In addition to tapentadol, there has been an increasing interest in using duloxetine, as a part of multimodal analgesic protocol, for postoperative pain management in patients receiving elective orthopedic surgery.  Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), approved by the United States Food and Drug Administration (US FDA) for the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain such as osteoarthritis, chronic back pain, etc. In this OE Original, we conduct a systematic review and meta-analysis to examine the RCT evidence regarding the safety and efficacy of duloxetine in terms of controlling acute postoperative pain and reducing opioid consumption in patients undergoing elective orthopedic surgery. Moreover, we also hypothesized that the....